{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"65.7","upperLimit":"97.9","value":"81.8"},{"groupId":"OG001","lowerLimit":"59.8","upperLimit":"100","value":"80.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.9","upperLimit":"72.9","value":"66.9"},{"groupId":"OG001","lowerLimit":"70.9","upperLimit":"81.5","value":"76.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"256"},{"groupId":"OG001","value":"268"}],"units":"Participants"}],"title":"Not Hispanic or Latino"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"68.4","upperLimit":"100","value":"88.9"},{"groupId":"OG001","lowerLimit":"53.5","upperLimit":"100","value":"83.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"OG000","value":"287"},{"groupId":"OG001","value":"290"}],"units":"Participants"}],"description":"NIH-required analysis. Overall survival time is defined as time from registration/randomization to the date of death from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. Analysis occurred after all participants had potentially been on study for at least 5 years. The distributions of survival times are compared, which is reported in the statistical analysis results. Five-year rates are provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Radiation therapy: 60 Gy intensity-modulated radiotherapy (IMRT), 2 Gy/day in 30 fractions (5 days a week for 6 weeks).","id":"OG000","title":"IMRT"},{"description":"Radiation therapy (RT): 60 Gy IMRT, 2 Gy/day in 30 fractions (5 days a week for 6 weeks).\n\nCetuximab: 400 mg/m\\^2 intravenously (IV) at least 5 days prior to IMRT; 250 mg/m\\^2 IV once a week for 6 weeks during RT and continuing 4 weeks after RT.","id":"OG001","title":"IMRT Plus Cetuximab"}],"paramType":"NUMBER","populationDescription":"Randomized eligible participants. Data were stratified by ethnicity.","reportingStatus":"POSTED","timeFrame":"From randomization to date of death or last follow-up. Maximum follow-up at time of analysis was 12.1 years.","title":"Percentage of Participants Alive (Overall Survival) by Ethnicity","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"percentage of participants"}